Skip to main content
S&P 5007,696.02+1.68%DOW53,299.35+2.92%NASDAQ25,806.01+1.71%BTC$80,353.00+3.61%ETH$2,423.32+5.73%GOLD$4,073.00+3.37%OIL$88.31-8.10%
Smart Investors Daily
SID Premium
NS

AMEX · NSRX

Nasus Pharma Ltd.

Healthcare · Biotechnology

$3.20

Down-$0.10 (-3.12%)

Updated Nov 4, 2026, 5:17 PM

SID Score

2.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
58.89M
P/E ratio
-38.44
Dividend yield
0.00%
52-week range
$1.98 – $5.20
Volume
15.74K
Avg. volume
13.21K

Price performance · NSRX

NSRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

NSRX closed at $3.20 after 21 trading sessions, down 16.67% for the selected period.

Last close
$3.20
Period change
-16.67%
Period low
$3.06
Period high
$3.84
Daily close
View OHLC price history
NSRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$3.31$3.395$3.10$3.2015.74K
Nov 2, 2026$3.10$3.32$3.10$3.19914.75K
Oct 30, 2026$3.23$3.27$3.07$3.074.89K
Oct 29, 2026$3.34$3.40$3.19$3.1910.58K
Oct 28, 2026$3.39$3.40$3.19$3.345.39K
Oct 27, 2026$3.2846$3.50$3.2846$3.3210.98K
Oct 26, 2026$3.41$3.6067$3.41$3.4915.05K
Oct 23, 2026$3.20$3.585$3.09$3.4935.24K
Oct 22, 2026$3.31$3.61$3.12$3.2333.36K
Oct 21, 2026$3.20$3.63$3.03$3.0644.42K
Oct 20, 2026$3.21$3.33$3.21$3.2419.85K
Oct 19, 2026$3.13$3.39$3.09$3.20519.08K
Oct 16, 2026$3.0901$3.24$3.0901$3.1815.04K
Oct 15, 2026$3.22$3.22$3.0501$3.1656.52K
Oct 14, 2026$3.23$3.3099$3.08$3.1813.34K
Oct 13, 2026$3.22$3.33$3.10$3.1613.42K
Oct 12, 2026$3.33$3.44$3.2423$3.3230.88K
Oct 9, 2026$3.63$3.6612$3.44$3.5116.92K
Oct 8, 2026$3.78$3.78$3.50$3.6314.03K
Oct 7, 2026$3.855$3.91$3.7569$3.7759.57K
Oct 6, 2026$3.88$3.9129$3.7701$3.8417.22K

Latest NSRX news

The latest Smart Investors Daily articles mentioning NSRX.

Stock researchCompany · Overview

NSRX research

Overview

Company profile and research snapshot.

Company profile

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.00
Implied upside
—
Analysts
—
NSRX recent ratings
DateFirmRatingTarget
Oct 30, 2026Maxim GroupBuy—
Mar 26, 2026CitizensMarket Outperform—
Dec 18, 2025CitizensMarket Outperform—
Sep 29, 2025Laidlaw & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 pharmacokinetic (PK) trial of NS003, its proprietary intranasal powder formulation of ondan

Yahoo · Sep 14, 2026

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional Pivotal Study is planned for the fourth quarter of 2026; topline data readout anticipated first quarter 2027 TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) (“Nasus Pharma” or the “Company”), a cli

Yahoo · Sep 8, 2026

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management team will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 in New York, NY, at the Lotte New York Palace hotel. The Company’s presentation will be avai

Benzinga · Aug 17, 2026

Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate

Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17) per share from the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By